Long-term fenofibrate therapy did not reduce major coronary events but may reduce total CVD events in type 2 diabetes mellitus

May 2006
ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p65
Academic Journal
The article discusses a study which determines the effect of long-term fenofibrate therapy on coronary heart disease events in patients with type 2 diabetes mellitus. 9795 patients, who had a World Health Organization diagnosis of type 2 diabetes, total cholesterol level 3 to 6.5 mmol/L, and a triglyceride level of 1 to 5 mmol/L, with no clear indication for lipid-modifying therapy were included in the study. The study found that in patients with type 2 diabetes mellitus, long-term fenofibrate therapy did not reduce major coronary events but may reduce total cardiovascular disease events.


Related Articles

  • Triglycerides, apo C3 and Lp B:C3 and cardiovascular risk in Type II diabetes. Gervaise, N.; Garrigue, M. A.; Lasfargues, G.; Lecomte, P. // Diabetologia;Jun2000, Vol. 43 Issue 6, p703 

    Aims/hypothesis. Cardiovascular complications and particularly coronary heart disease are the main causes of morbidity and mortality in Type II (non-insulin-dependent) diabetes mellitus. Some studies have shown that hypertriglyceridaemia in diabetes is an independent cardiovascular risk factor....

  • Lifestyle Risk Factors and Cardiovascular Disease in Cubans and Cuban Americans. Burroughs Peña, Melissa S.; Patel, Dhaval; Leyva, Delfin Rodríguez; Khan, Bobby V.; Sperling, Laurence // Cardiology Research & Practice;2012, p1 

    Cardiovascular disease is the leading cause of mortality in Cuba. Lifestyle risk factors for coronary heart disease (CHD) in Cubans have not been compared to risk factors in Cuban Americans. Articles spanning the last 20 years were reviewed. The data on Cuban Americans are largely based on the...

  • INSIGHTS INTO OBESITY'S PATHOGENESIS AND PHARMACOLOGICAL MANAGEMENT. Galoiu, S. // Acta Endocrinologica (1841-0987);2015, Vol. 11 Issue 2, p262 

    Obesity is an increasing public health problem, the fifth leading risk for global deaths according to WHO. It is associated with major comorbidities, such as type 2 diabetes mellitus, ischemic heart disease, hypertension, dyslipidemia, sleep apnea, osteoarthritis, nonalcoholic fatty liver...

  • FIELD: Fenofibrate reduced CVD risk among patients with type 2 diabetes, metabolic syndrome.  // Cardiology Today;Apr2009, Vol. 12 Issue 4, p1 

    The article discusses research which found that patients with type 2 diabetes and metabolic syndrome had the greatest five-year-risk for cardiovascular disease and were likely to reap the greatest benefits from fenofibrate treatment.

  • Long-term fenofibrate therapy did not reduce major coronary events but may reduce total CVD events in type 2 diabetes mellitus: COMMENTARY. McQueen, Matthew // ACP Journal Club;May/Jun2006, Vol. 144 Issue 3, p64 

    The article presents comments of the author on a study which found that long-term fenofibrate therapy did not reduce major coronary events but may reduce total CVD events in type 2 diabetes mellitus. It is disappointing that fenofibrate did not reduce fatal myocardial infarcation or coronary...

  • Diabetes and your heart.  // Prevention India;Apr2011, p6 

    The article reports that cardiovascular disease (CVD) is the commonest cause of death in people with type 2 diabetes. According to the International Diabetes Federation, more than 30 percent of type 2 diabetics will have co-existent coronary heart disease and this shows that diabetes increases...

  • Type 2 Diabetes As An Inflammatory Cardiovascular Disorder. Ziegler, D. // Current Molecular Medicine;May2005, Vol. 5 Issue 3, p309 

    Type 2 diabetes carries a 2-6-fold increased risk of cardiovascular disease (CVD) and death. Indeed, the risk of major cardiovascular events in Type 2 diabetic patients without history of coronary heart disease (CHD) is equivalent to that observed in non-diabetic subjects with CHD. However,...

  • Diabetes and Coronary Risk Equivalency. Grundy, Scott M. // Diabetes Care;Feb2006, Vol. 29 Issue 2, p457 

    Comments on a study which reported the incidence of coronary heart disease in type 2 diabetes patients in southwestern Oklahoma, central Arizona and North and South Dakota. Review of related studies; Discussion on the research findings; Approach proposed by the National Cholesterol Education...

  • Atorvastatin reduced risk for major CV events in patients with CAD, CKD, diabetes. Blumenthal, Roger S. // Endocrine Today;10/10/2008, Vol. 6 Issue 18, p18 

    The article discusses research on the impact of lipid-lowering with high-dose atorvastatin on the risk for major cardiovascular events in patients with coronary artery disease, type 2 diabetes and chronic kidney disease (CKD). Results showed that patients with diabetes and CKD assigned to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics